MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
about
Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitorMelanoma: from melanocyte to genetic alterations and clinical optionsResistant mechanisms to BRAF inhibitors in melanomaRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerSomatic DNA mutation analysis in targeted therapy of solid tumoursUpdates in Therapy for Advanced MelanomaMelanoma: oncogenic drivers and the immune systemRecent advances in the treatment of melanoma with BRAF and MEK inhibitorsAmeloblastoma: A Review of Recent Molecular Pathogenetic DiscoveriesTrametinib: a MEK inhibitor for management of metastatic melanomaPathways and therapeutic targets in melanomaMelanoma brain metastases: an unmet challenge in the era of active therapyBeyond BRAF: where next for melanoma therapy?Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondActivated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated ProteinsCIViC databaseLoss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Mutant HRAS as novel target for MEK and mTOR inhibitorsTargeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.Beyond RAS and BRAF: a target rich disease that is ripe for pickingRAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screeningA novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent mannerNivolumab and ipilimumab versus ipilimumab in untreated melanomaSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandSequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panelMUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agentEvaluating melanoma drug response and therapeutic escape with quantitative proteomicsCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
P2860
Q21195751-568103D4-2D7F-4E16-8171-9A1CEA741263Q21284811-39B50A49-F1E5-4079-9846-2BCAA0C44F79Q26739717-47FDBB24-F362-49EF-91C8-546748D37DA6Q26740631-19806663-497E-41BD-B5B5-4B002D945B37Q26747247-DD395F7D-1B06-43ED-A40D-19BFC9C6F074Q26770324-0A83416C-E104-4635-ADB8-95491F233F5EQ26771119-25515F6A-0480-4E37-81AD-95F0F8BEB407Q26775598-B85733EC-6466-49FF-B124-10EF971DC950Q26778769-9677B0F7-5B03-461D-B566-8443212DCBD8Q26781648-85E7BDAF-4E14-4ACF-985F-0131B21F98EFQ26782976-FF11CFFB-6169-4597-9508-2077D088B428Q26865736-822B6941-0E36-41BE-B262-333E71AF6497Q26995622-901132E0-1A27-4A6A-A2C1-FA3011BE57D6Q27006853-C5A25CBE-E200-4983-A372-D69746FE95F4Q27026323-A7D86E98-11CA-463F-A46F-EAF445AEF47BQ27027458-FF9A9C69-970F-43FB-AD8C-35CA3FC9D33CQ27612411-A3CA0B8C-BE6D-4888-9A18-D06AB4C8AEBDQ27852894-85EFEFEA-6D95-4B27-8DBE-1884BFE95EFAQ27853021-9C42710C-6E89-45DC-99C9-AC423E90515CQ27853104-78049C32-A367-4974-9A64-0E862DB55E0EQ27853238-427C1CBE-C045-48C3-9653-A2A0D5A192DFQ27853330-748FD4E0-31B1-48A4-B710-A6E9EFBFE30FQ28066095-A2A66FA5-B428-4FA8-AD35-E70DF16AF8D2Q28260541-7FF01992-925B-4862-A1E2-849539CA5C22Q28596034-E75142D6-265C-453B-9853-95042641592DQ28817145-E1B425EB-6EE6-4F37-B3A8-0E46B8985057Q29620657-FE813618-428C-46C2-AE2C-B11465F44188Q30239901-3A30DC0A-1F5F-4548-BA32-6A79AB31D270Q30313298-1FB02ACD-7D0C-4C6A-ADC7-EEF570A97908Q30491702-232BA18E-E7B2-4F72-811D-8080E8EA89AEQ30746423-5C22A419-AD34-4688-9774-D46228ED8183Q30828178-C4C65CFF-07D8-429A-8787-CE3663BB583BQ33556937-74270500-99E8-4027-BDC2-DCF1B225C1A9Q33560928-62B1EDB3-DA07-42AA-A55A-EC299D773B13Q33566681-28EC6BF5-ADAA-4B9A-96DA-ADB011F52301Q33699641-DCEF2F5C-1BDE-4FBF-93BD-087D5FFEDACBQ33704699-7C8A2764-54E8-434F-B4D5-548598CF50AEQ33728258-AC16BB2B-6A9F-421D-89CF-D2F2D55030A0Q33850665-56CBD059-36EB-4ACD-A58F-C3679474CE69Q33918101-4F12E367-1B15-4291-AD3C-4E11FD811F9E
P2860
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@ast
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@en
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@nl
type
label
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@ast
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@en
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@nl
prefLabel
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@ast
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@en
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@nl
P2093
P50
P3181
P1433
P1476
MEK162 for patients with advan ...... sed, open-label phase 2 study.
@en
P2093
Angela Zubel
Annie St-Pierre
Carla Ml van Herpen
Carola Berking
Christian U Blank
Faiz Niazi
J Thaddeus Beck
Malte Peters
Paola Queirolo
Sanjiv S Agarwala
P304
P3181
P356
10.1016/S1470-2045(13)70024-X
P577
2013-03-01T00:00:00Z